Discovering, Developing and Delivering Gene Therapies. Transforming Lives.

GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on identifying, in-licensing and developing transformative gene therapies. GeneVentiv has two first-in-class gene therapies for patients with significant unmet needs. GENV-HEM is a gene therapy for all hemophilias, including inhibitor patients, and without the durability issues that have plagued Factor VIII gene therapies. GENV-002 is a first-in-class gene editing therapy for both the Infantile Onset (IOPD) and Late Onset (LOPD) forms of Pompe disease that stably integrates a functional GAA transgene offering lifelong enzyme production, something that other gene therapies are unable to achieve. With these gene therapies we can transform the lives of 270,000+ developed world patients.

Explore, learn more and grow with us.